Home Tags ADC Therapeutics

Tag: ADC Therapeutics

Featured Image: ADC Therapeutics Booth at AACR 2018 Courtesy: © 2017 – 2018. Sunvalley Communication, LLC / Evan Wendt. Used with permission.

Freenome Enters Biomarker Development Collaboration with ADC Therapeutics

Swiss-based ADC Therapeutics, an oncology-drug development company specializes in the development of antibody drug conjugates (ADCs), and Freenome, a biotech company pioneering the a...

SOPHiA Genetics and ADC Therapeutics Partner for Biomarker Discovery in Pivotal...

ADC Therapeutics and SOPHiA GENETICS have entered into a collaboration to identify genomic markers associated with clinical response to loncastuximab tesirine (ADCT-402), an antibody...
Featured Image: View of Lugano old town with mountains in the background, Switzerland. Courtesy: © 2017. Fotolia. Used with permission.

Pyrrolobenzodiazepine-based ADCs Demonstrate Potential in R/R Lymphomas

The International Conference on Malignant Lymphoma (ICML) has, since its first edition in 1981, become one of the must-attend conferences for the scientific community...
Scientist pipetting

ADC Therapeutics Expands Agreement with Synaffix

The Netherlands-based biotechnology company Synaffix, which develops clinical-stage technologies for the development of best-in-class antibody-drug conjugates or ADCs, confirmed that ADC Therapeutics has triggered...

ADC Therapeutics and Adagene Enter into a Discovery Collaboration and License...

ADC Therapeutics, headquartered in Lausanne, Switzerland, and Adagene, a clinical stage biotech company based in Suzhou, China and San Francisco, USA, have entered into...

First Patient Dosed in Phase I Trial with Pyrrolobenzodiazepine-based Antibody-drug conjugate...

The development of proprietary, pyrrolobenzodiazepine-based, antibody-drug conjugates or ADCs targeting AXL, has entered a news phase with the dosing of the first patient in...

ADC Therapeutics Ends ADCT-502 Development Program

Earlier this week Lausanne, Switzerland-based ADC Therapeutics, an oncology drug discovery and development company specializing in the development of proprietary antibody-drug conjugates or ADCs...

Interim Data Shows Favorable Tolerability and Efficacy Results of ADCT-301 in...

Interim results from an ongoing Phase I, open label, dose-escalating study evaluating ADCT-301, being developed by ADC Therapeutics for the treatment of relapsed or refractory...

First Patient with Advanced Solid Tumors with HER2 Expression Dosed in...

A first patient with advanced solid tumors with HER2 Expression was dosed in a phase I clinical trial with ADCT-502. The investigational drug being...

Successful Funding Round Expected to Accelerate ADC Therapeutics’ Clinical Development

Swiss Biotech company ADC Therapeutics, an oncology drug discovery and development company specializing in the development of proprietary antibody-drug conjugates or ADCs for the treatment...

FEATURED RESOURCES